Last reviewed · How we verify
NCT06856096
PET/MRI Artificial Intelligence Reconstruction Algorithm AIR Recon DL Image Quality Evaluation and Clinical Study
NA trial testing PET/MRI in Parkinson's Syndrome in 65 participants. Participants enrolled and being followed up; not accepting new ones.
15 January 2027
Quick facts
| Lead sponsor | Xijing Hospital |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | sequential |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 65 |
| Start date | 10 February 2025 |
| Primary completion | 15 January 2027 |
| Estimated completion | 15 January 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- PET/MRI
Conditions studied
- Parkinson's Syndrome — all drugs for Parkinson's Syndrome →
Sponsor
Xijing Hospital
Who can join
Adults 18 to 75, any sex, with Parkinson's Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
PET/MRI artificial intelligence reconstruction algorithm AIR Recon DL image quality evaluation and clinical study
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06856096
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PET/MRI
Trials testing the same drug.
- NCT07523997 — Imaging of Endometriosis With Total-body PET-CT (PET-Endo) · not yet recruiting
- NCT07010484 — Using Novel Imaging to Rethink Diagnostic and Treatment Strategies for Polymyalgia Rheumatica · recruiting
- NCT06947759 — Application of 18F-FDG PET/MRI for Initial Staging in Locally Advanced Nasopharyngeal Carcinoma · not yet recruiting
- NCT05954507 — Evaluation of the Prognostic Value of PET/MRI in Cardiac Sarcoidosis · NA · recruiting
- NCT04668872 — Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation · recruiting
Other Xijing Hospital trials
Trials by the same sponsor.
- NCT07532096 — Extended Sentinel Lymph Node Biopsy With Methylene Blue Single Tracer Post-Neoadjuvant Therapy for Node-Positive Breast · NA · not yet recruiting
- NCT07519018 — TIS for Drug Resistant TLE · NA · not yet recruiting
- NCT07518992 — Correlation Between Preoperative Sleep and Postoperative Brain and Renal Dysfunction · not yet recruiting
- NCT07466303 — Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer · Phase 2 · not yet recruiting
- NCT07474142 — A Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve P · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06856096 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xijing Hospital
- Last refreshed: 4 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06856096.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing